Moderna
MRNA
$49.04
-1.98%
Moderna, Inc. is a commercial-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, operating within the dynamic and high-risk biotech industry. The company established itself as a dominant platform leader through the rapid validation and commercial success of its COVID-19 vaccine, which propelled it from a development-stage entity to a major commercial player. The current investor narrative is intensely focused on the company's transition beyond its pandemic windfall, balancing near-term financial pressures from declining COVID vaccine revenue against the promise of its expansive pipeline across infectious diseases, oncology, and rare diseases, with recent headlines highlighting both significant legal settlements and strong operational sales performance.…
MRNA
Moderna
$49.04
Related headlines
MRNA 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Moderna's 12-month outlook, with a consensus price target around $63.75 and implied upside of +30.0% versus the current price.
Average Target
$63.75
8 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
8
covering this stock
Price Range
$39 - $64
Analyst target range
Analyst coverage is limited with only 8 analysts providing estimates, indicating this is a stock with higher uncertainty and less institutional consensus typical of a volatile biotech name. The consensus sentiment appears mixed, as evidenced by recent institutional ratings which include actions like 'Overweight' from Piper Sandler but also 'Underperform' from B of A Securities and Leerink Partners, and 'Sector Perform' or 'Neutral' from several others, reflecting the binary nature of the investment thesis. The target price range is not explicitly provided in the data, but the wide dispersion in revenue estimates for the upcoming period—with a low of $5.58 billion and a high of $10.08 billion—signals extremely high uncertainty and low conviction among analysts regarding the company's near-term commercial trajectory, which contributes to the stock's elevated volatility.
Bulls vs Bears: MRNA Investment Factors
The investment debate for Moderna is a classic biotech tension between a promising, platform-based future and a harsh, cash-burning present. The bull case is anchored by a robust pipeline of 35 candidates and a fortress balance sheet that provides a multi-year runway. The bear case is dominated by severe revenue contraction, deep unprofitability, and high uncertainty, as reflected in the elevated short interest and negative recent momentum. Currently, the bearish evidence holds stronger sway due to the tangible, near-term financial deterioration and lack of clear commercial catalysts to offset the COVID revenue cliff. The single most important tension is the timeline for pipeline success versus the cash burn rate; if key late-stage assets fail or are delayed, the company's financial cushion could erode rapidly, invalidating the long-term platform thesis.
Bullish
- Robust Platform & Expansive Pipeline: The company has 35 mRNA development candidates in clinical studies across infectious diseases, oncology, and rare diseases, providing multiple shots on goal for future revenue. This pipeline is the core long-term value driver, as the market has already priced out the COVID-19 windfall, evidenced by the PS ratio collapsing from over 200x to 5.90x.
- Strong Balance Sheet & Liquidity: A current ratio of 3.29 and a low debt-to-equity of 0.22 provide a substantial financial runway to fund R&D through the current cash-burn phase. With $2.595 billion in cash reserves as of Q4 2025, the company can sustain its negative free cash flow of -$2.054 billion TTM for over a year without needing dilutive financing.
- Significant Technical Recovery Potential: Despite a 67.85% one-year price surge, the stock trades at only 39% of its 52-week range, closer to the $22.28 low than the $59.55 high. This positioning suggests the rally from deeply oversold levels has substantial room to continue if fundamental catalysts emerge, with a breakout above $59.55 signaling a renewal of the bullish thesis.
- Legal Overhang Partially Cleared: Recent news highlights a $950 million settlement that resolved a major legal threat, removing a significant source of uncertainty. While a subsequent legal expense drove a negative stock reaction, the resolution of core litigation allows management to focus on pipeline execution and commercial strategy.
Bearish
- Severe Revenue Contraction & Volatility: Q4 2025 revenue of $678 million represents a 29.1% year-over-year decline, with quarterly revenue swinging wildly from $1.856 billion in Q3 2024 to a low of $107 million in Q1 2025. This extreme lumpiness reflects the unsustainable, post-pandemic collapse of COVID-19 vaccine sales, creating high earnings volatility and low visibility.
- Deeply Unprofitable with Cash Burn: The company posted a net margin of -121.8% and net income of -$826 million in Q4 2025, with gross margin compressing to 33.3% from pandemic peaks above 70%. With TTM free cash flow at -$2.054 billion, the company is burning cash rapidly to fund its pipeline, creating a race against time to achieve profitability before reserves deplete.
- High Short Interest & Analyst Uncertainty: A short ratio of 9.78 indicates significant bearish sentiment and skepticism about the near-term outlook. This is compounded by low analyst coverage (only 8 analysts) and a wide dispersion in revenue estimates for the upcoming period, ranging from $5.58 billion to $10.08 billion, signaling extremely low conviction.
- Elevated Volatility & Negative Momentum: A beta of 1.336 makes the stock 34% more volatile than the market, amplifying downside risk during negative clinical or regulatory news. Recent momentum has turned sharply negative, with the stock down 9.31% over the past month and underperforming the S&P 500 by 19.29 percentage points, suggesting a loss of bullish conviction.
MRNA Technical Analysis
The stock is in a pronounced recovery trend from deeply oversold levels, evidenced by a staggering 67.85% one-year price appreciation, yet it is currently trading at approximately 39% of its 52-week range, positioned closer to the $22.28 low than the $59.55 high, suggesting the recovery is substantial but still leaves significant room for further upside if the fundamental thesis improves. Recent momentum has turned negative, with the stock declining 9.31% over the past month and gaining only 2.95% over the past three months, indicating a significant deceleration and potential consolidation or pullback after the powerful rally from late 2025 lows. Key technical support is anchored at the 52-week low of $22.28, while resistance looms at the 52-week high of $59.55; a sustained breakout above resistance would signal a renewal of the bullish thesis, while a breakdown below support would invalidate the recovery. The stock's beta of 1.336 indicates it is approximately 34% more volatile than the broader market, which is critical for risk management given its biotech profile and sensitivity to clinical and regulatory catalysts.
Beta
1.06
1.06x market volatility
Max Drawdown
-35.5%
Largest decline past year
52-Week Range
$22-$60
Price range past year
Annual Return
+107.4%
Cumulative gain past year
| Period | MRNA Return | S&P 500 |
|---|---|---|
| 1m | -9.6% | +5.6% |
| 3m | +16.1% | +8.4% |
| 6m | +98.0% | +10.0% |
| 1y | +107.4% | +25.2% |
| ytd | +58.9% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MRNA Fundamental Analysis
Revenue is in a state of severe contraction and high volatility, with the most recent quarterly figure at $678 million representing a 29.1% year-over-year decline, and the multi-quarter trend shows wild swings from $1.856 billion in Q3 2024 to a low of $107 million in Q1 2025, reflecting the lumpy, post-pandemic normalization of COVID vaccine sales. The company is deeply unprofitable, posting a net income of -$826 million and a net margin of -121.8% for Q4 2025, with gross margin compressing dramatically to 33.3% from levels above 70% during the pandemic peak, indicating severe pressure on profitability as high-margin vaccine revenue recedes and R&D costs remain elevated. The balance sheet remains robust with a strong current ratio of 3.29 and a manageable debt-to-equity ratio of 0.22, but free cash flow over the trailing twelve months is deeply negative at -$2.054 billion, highlighting that the company is burning significant cash to fund its extensive pipeline development and will rely on its substantial cash reserves of $2.595 billion (as of Q4 2025) to bridge to future profitability.
Quarterly Revenue
$678000000.0B
2025-12
Revenue YoY Growth
-0.29%
YoY Comparison
Gross Margin
+0.33%
Latest Quarter
Free Cash Flow
$-2.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MRNA Overvalued?
Given the company's negative net income and negative EBITDA, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio stands at 5.90x, while the forward-looking metric is not explicitly provided but can be inferred from analyst revenue estimates; the market is valuing the stock based on its sales multiple as profitability remains elusive. Compared to industry averages, a PS ratio of 5.90x is difficult to contextualize without a specific sector benchmark, but it represents a significant de-rating from the exorbitant multiples seen during the pandemic revenue peak, suggesting the market has heavily discounted the sales base. Historically, the stock's own PS ratio has collapsed from a peak above 200x in early 2024 to the current 5.90x, placing it near the bottom of its own historical band and indicating the market is pricing in a scenario of sustained revenue decline and limited near-term pipeline contributions, presenting a potential value opportunity if pipeline catalysts materialize.
PE
-4.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -13x~495x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-4.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and center on the company's transition from pandemic windfall to sustainable commercial operations. Revenue has contracted 29.1% YoY in Q4 2025 and exhibits extreme quarterly volatility, reflecting dependence on a single, declining product. Gross margin has collapsed from over 70% to 33.3%, indicating severe profitability pressure as high-margin vaccine sales recede. While the balance sheet is strong, the company is burning cash at a rate of -$2.054 billion TTM to fund its 35-candidate pipeline, creating a race against time to achieve commercial success before its $2.595 billion cash reserve is depleted.
Market & Competitive Risks are heightened by the stock's valuation and sector dynamics. The trailing PS ratio of 5.90x, while down from historical extremes, is difficult to justify without near-term profitability, leaving the stock vulnerable to multiple compression if growth disappoints. The biotech sector is intensely competitive and highly sensitive to clinical trial outcomes and regulatory decisions. The stock's beta of 1.336 confirms its high sensitivity to market sentiment and sector rotations, as seen in recent news where geopolitical shifts triggered sharp moves in growth stocks. Ongoing legal disputes, such as the recent lawsuit from BioNTech, add further intellectual property and commercial uncertainty.
The Worst-Case Scenario involves a combination of pipeline failures, accelerated cash burn, and a sustained risk-off environment for biotech. Specific events would include negative Phase 3 data for lead non-COVID pipeline assets, leading to analyst downgrades and a withdrawal of institutional support. Coupled with faster-than-expected erosion of the remaining COVID vaccine revenue, this could accelerate the cash burn, forcing dilutive equity raises or strategic cuts to the R&D program. In this adverse scenario, the stock could realistically re-test its 52-week low of $22.28, representing a downside of approximately -51% from the current price of $45.37, potentially exacerbated by the high short interest creating a crowded exit.